Format

Send to

Choose Destination
Anaerobe. 2018 Aug;52:122-124. doi: 10.1016/j.anaerobe.2018.06.016. Epub 2018 Jul 4.

In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species.

Author information

1
R. M. Alden Research Laboratory, Santa Monica, CA, 90404, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, 90073, USA. Electronic address: ejcgmd@aol.com.
2
R. M. Alden Research Laboratory, Santa Monica, CA, 90404, USA.

Abstract

Eravacycline, a novel fluorocycline antibiotic, has been evaluated against complicated mixed aerobic/anaerobic intra-abdominal infections but scant supporting in vitro data against anaerobes has been published. We found that eravacycline had good anaerobic in vitro activity with MICs of 4 μg/ml or less against all Bacteroides and Parabacteroides strains tested, except for two B. ovatus strains that had MICs of 8 μg/ml and one strain that had an MIC of 16 μg/ml. Eravacycline was four-to-eight fold more active than tigecycline.

KEYWORDS:

Anaerobes; Bacteroides fragilis; Eravacycline; Tigecycline

PMID:
30018028
DOI:
10.1016/j.anaerobe.2018.06.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center